EVALUATION OF NEUTROPHIL-LYMPHOCYTE RATIO IN PATIENTS WITH MYCOSIS FUNGOIDES
(Abstract release date: 05/19/16)
EHA Library. Eren R. 06/09/16; 134947; PB2047
Dr. Rafet Eren
Contributions
Contributions
Abstract
Abstract: PB2047
Type: Publication Only
Background
Neutrophil lymphocyte ratio (NLR), an indicator of inflammation, has been lately demonstrated as a prognostic factor in various lymphoproliferative disorders. However, the effects of NLR has not been investigated in mycosis fungoides (MF) patients yet.
Aims
The aim of this study is to investigate the relationship between the neutrophil-lymphocyte ratio (NLR) and treatment demand (systemic PUVA and/or chemotherapy), time to treatment, progression in stage, time to progression in stage in MF patients.
Methods
The data of 117 patients, who were followed with the diagnosis of MF at Department of Dermatology in Istanbul Training and Research Hospital between April 2006 and January 2016, were reviewed retrospectively. Neutrophil-lymphocyte ratio was calculated from complete blood count of patients at the time of diagnosis. The cut-off score for NLR was determined as 2 according to the median NLR level which was 1.96. Statistical evaluation was made by SPSS 15 package program. x2 Fisher’s exact test was used for evaluating categorical values and Mann Whitney U test for continuous values in patient groups.
Results
At the time of diagnosis, the median age of patients was 54 years (range, 21-90). 62 (53%) of the patients were female and 55 (47%) were male. 60 (51.3%) patients had stage Ia, 18 (15.4%) had stage Ib, 35 (29.9%) had stage IIa, 1 (0.9%) had stage IIIa and 3 (2.6%) had stage IVa disease. 77 (65.8%) patients required treatment during follow up. The median time from diagnosis to treatment was 2 (range, 0-64) months. 63 (53.8%) patients showed progression in disease stage. The median time from diagnosis to progression in stage was 23 (1-108) months. There was no significant difference in treatment necessity, time to treatment, progression in stage, time to progression in stage in patients with a NLR≥ 2 and NLR< 2 (p=0.331, 0.987, 0.065, 0.119 respectively)
Conclusion
Although NLR has been demonstrated to have prognostic role in various lymphoporliferative disorders, it seems that there is no association between the NLR and treatment demand (systemic PUVA and/or chemotherapy), time to treatment, progression in stage, time to progression in stage in mycosis fungoides (MF) patients
Session topic: E-poster
Keyword(s): Lymphocyte, Mycosis fungoides, Neutrophil
Type: Publication Only
Background
Neutrophil lymphocyte ratio (NLR), an indicator of inflammation, has been lately demonstrated as a prognostic factor in various lymphoproliferative disorders. However, the effects of NLR has not been investigated in mycosis fungoides (MF) patients yet.
Aims
The aim of this study is to investigate the relationship between the neutrophil-lymphocyte ratio (NLR) and treatment demand (systemic PUVA and/or chemotherapy), time to treatment, progression in stage, time to progression in stage in MF patients.
Methods
The data of 117 patients, who were followed with the diagnosis of MF at Department of Dermatology in Istanbul Training and Research Hospital between April 2006 and January 2016, were reviewed retrospectively. Neutrophil-lymphocyte ratio was calculated from complete blood count of patients at the time of diagnosis. The cut-off score for NLR was determined as 2 according to the median NLR level which was 1.96. Statistical evaluation was made by SPSS 15 package program. x2 Fisher’s exact test was used for evaluating categorical values and Mann Whitney U test for continuous values in patient groups.
Results
At the time of diagnosis, the median age of patients was 54 years (range, 21-90). 62 (53%) of the patients were female and 55 (47%) were male. 60 (51.3%) patients had stage Ia, 18 (15.4%) had stage Ib, 35 (29.9%) had stage IIa, 1 (0.9%) had stage IIIa and 3 (2.6%) had stage IVa disease. 77 (65.8%) patients required treatment during follow up. The median time from diagnosis to treatment was 2 (range, 0-64) months. 63 (53.8%) patients showed progression in disease stage. The median time from diagnosis to progression in stage was 23 (1-108) months. There was no significant difference in treatment necessity, time to treatment, progression in stage, time to progression in stage in patients with a NLR≥ 2 and NLR< 2 (p=0.331, 0.987, 0.065, 0.119 respectively)
Conclusion
Although NLR has been demonstrated to have prognostic role in various lymphoporliferative disorders, it seems that there is no association between the NLR and treatment demand (systemic PUVA and/or chemotherapy), time to treatment, progression in stage, time to progression in stage in mycosis fungoides (MF) patients
Session topic: E-poster
Keyword(s): Lymphocyte, Mycosis fungoides, Neutrophil
Abstract: PB2047
Type: Publication Only
Background
Neutrophil lymphocyte ratio (NLR), an indicator of inflammation, has been lately demonstrated as a prognostic factor in various lymphoproliferative disorders. However, the effects of NLR has not been investigated in mycosis fungoides (MF) patients yet.
Aims
The aim of this study is to investigate the relationship between the neutrophil-lymphocyte ratio (NLR) and treatment demand (systemic PUVA and/or chemotherapy), time to treatment, progression in stage, time to progression in stage in MF patients.
Methods
The data of 117 patients, who were followed with the diagnosis of MF at Department of Dermatology in Istanbul Training and Research Hospital between April 2006 and January 2016, were reviewed retrospectively. Neutrophil-lymphocyte ratio was calculated from complete blood count of patients at the time of diagnosis. The cut-off score for NLR was determined as 2 according to the median NLR level which was 1.96. Statistical evaluation was made by SPSS 15 package program. x2 Fisher’s exact test was used for evaluating categorical values and Mann Whitney U test for continuous values in patient groups.
Results
At the time of diagnosis, the median age of patients was 54 years (range, 21-90). 62 (53%) of the patients were female and 55 (47%) were male. 60 (51.3%) patients had stage Ia, 18 (15.4%) had stage Ib, 35 (29.9%) had stage IIa, 1 (0.9%) had stage IIIa and 3 (2.6%) had stage IVa disease. 77 (65.8%) patients required treatment during follow up. The median time from diagnosis to treatment was 2 (range, 0-64) months. 63 (53.8%) patients showed progression in disease stage. The median time from diagnosis to progression in stage was 23 (1-108) months. There was no significant difference in treatment necessity, time to treatment, progression in stage, time to progression in stage in patients with a NLR≥ 2 and NLR< 2 (p=0.331, 0.987, 0.065, 0.119 respectively)
Conclusion
Although NLR has been demonstrated to have prognostic role in various lymphoporliferative disorders, it seems that there is no association between the NLR and treatment demand (systemic PUVA and/or chemotherapy), time to treatment, progression in stage, time to progression in stage in mycosis fungoides (MF) patients
Session topic: E-poster
Keyword(s): Lymphocyte, Mycosis fungoides, Neutrophil
Type: Publication Only
Background
Neutrophil lymphocyte ratio (NLR), an indicator of inflammation, has been lately demonstrated as a prognostic factor in various lymphoproliferative disorders. However, the effects of NLR has not been investigated in mycosis fungoides (MF) patients yet.
Aims
The aim of this study is to investigate the relationship between the neutrophil-lymphocyte ratio (NLR) and treatment demand (systemic PUVA and/or chemotherapy), time to treatment, progression in stage, time to progression in stage in MF patients.
Methods
The data of 117 patients, who were followed with the diagnosis of MF at Department of Dermatology in Istanbul Training and Research Hospital between April 2006 and January 2016, were reviewed retrospectively. Neutrophil-lymphocyte ratio was calculated from complete blood count of patients at the time of diagnosis. The cut-off score for NLR was determined as 2 according to the median NLR level which was 1.96. Statistical evaluation was made by SPSS 15 package program. x2 Fisher’s exact test was used for evaluating categorical values and Mann Whitney U test for continuous values in patient groups.
Results
At the time of diagnosis, the median age of patients was 54 years (range, 21-90). 62 (53%) of the patients were female and 55 (47%) were male. 60 (51.3%) patients had stage Ia, 18 (15.4%) had stage Ib, 35 (29.9%) had stage IIa, 1 (0.9%) had stage IIIa and 3 (2.6%) had stage IVa disease. 77 (65.8%) patients required treatment during follow up. The median time from diagnosis to treatment was 2 (range, 0-64) months. 63 (53.8%) patients showed progression in disease stage. The median time from diagnosis to progression in stage was 23 (1-108) months. There was no significant difference in treatment necessity, time to treatment, progression in stage, time to progression in stage in patients with a NLR≥ 2 and NLR< 2 (p=0.331, 0.987, 0.065, 0.119 respectively)
Conclusion
Although NLR has been demonstrated to have prognostic role in various lymphoporliferative disorders, it seems that there is no association between the NLR and treatment demand (systemic PUVA and/or chemotherapy), time to treatment, progression in stage, time to progression in stage in mycosis fungoides (MF) patients
Session topic: E-poster
Keyword(s): Lymphocyte, Mycosis fungoides, Neutrophil
{{ help_message }}
{{filter}}